To see the other types of publications on this topic, follow the link: IBM PS/2.
Journal articles on the topic 'IBM PS/2'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'IBM PS/2.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Butler, Darrell L. "IBM PC, PS/2, and compatibles." Behavior Research Methods, Instruments, & Computers 21, no. 2 (March 1989): 341–42. http://dx.doi.org/10.3758/bf03205605.
Full text
2
Bradley, Drake R. "IBM PC, PS/2, and compatibles." Behavior Research Methods, Instruments, & Computers 22, no. 2 (March 1990): 266–67. http://dx.doi.org/10.3758/bf03203159.
Full text
3
Wisman, Ray, and Kyle Forinash. "A to D conversion with the IBM PS/2 for under $5." American Journal of Physics 59, no. 2 (February 1991): 187–88. http://dx.doi.org/10.1119/1.16609.
Full text
4
Bovens, Noël, and Marc Brysbaert. "IBM PC/XT/AT and PS/2 Turbo Pascal timing with extended resolution." Behavior Research Methods, Instruments, & Computers 22, no. 3 (May 1990): 332–34. http://dx.doi.org/10.3758/bf03209826.
Full text
5
Arnold, R. F., P. Halpern, G. R. Hogsett, B. T. Straka, C. Arasmith, and J. McElroy. "A numerically intensive computing environment: IBM 3090 and the PS/2 Model 80." IBM Journal of Research and Development 35, no. 1.2 (January 1991): 140–55. http://dx.doi.org/10.1147/rd.351.0140.
Full text
6
Gaichas, Lawrence E., and Gerald R. Culley. "Latin Skills I and Latin Skills II for the IBM PC and the PS/2, Version 1.0." Classical World 89, no. 5 (1996): 422. http://dx.doi.org/10.2307/4351835.
Full text
7
Micic, D., J. Jiang, L. Chen, T. Fan, F. Mu, A. Satija, N. Downes, et al. "P431 Teduglutide use and nutritional outcomes in short bowel syndrome with intestinal failure: a real-world claims database analysis." Journal of Crohn's and Colitis 15, Supplement_1 (May 1, 2021): S433—S434. http://dx.doi.org/10.1093/ecco-jcc/jjab076.555.
Full textAbstract:
Abstract Background Teduglutide (TED) is a glucagon-like peptide 2 analogue approved for the treatment of patients with short bowel syndrome (SBS) requiring parenteral support (PS). SBS is a rare condition resulting from a reduced absorptive surface area of the small intestine, most commonly due to inflammatory bowel disease (IBD). Patients with SBS with intestinal failure (SBS-IF) remain dependent on PS to maintain adequate calorie, fluid, electrolyte and micronutrient stability. In phase 3 clinical trials, TED reduced PS requirements in patients with SBS-IF. This study aimed to assess PS use and discontinuation rates among patients with SBS on TED using real-world data. Methods This retrospective cohort study of adults with SBS-IF (≥18 years) with ≥1 TED pharmacy claim(s) used the US-based administrative healthcare claims IBM MarketScan database (2009–2019). The first TED claim was defined as the index date. Patients required ≥6 months of continuous enrolment prior to index date (baseline period) and no history of malignancy. Primary analysis was conducted during the follow-up period (index date to earliest of continuous enrolment end or 2 years post-index). A sensitivity analysis was also conducted among the cohort during the TED utilization period (index date to the earliest of continuous enrolment end or TED discontinuation). Patients required PS use during both baseline and follow-up/TED utilization periods (primary and sensitivity analyses). PS discontinuation was defined as a PS utilization gap of ≥30 days. A generalized estimating equation linear regression model evaluated if PS use (days/week) changed significantly from baseline to selected time points post-index. Results Of 110 identified patients with SBS-IF, mean age was 53.4 (SD 13.2) years and 77 (70%) were women. Included were 51 (46%) patients with Crohn’s disease and 20 (18%) with ulcerative colitis. The main comorbidities were renal disease (23%) and liver disease (15%). PS frequency was 4.6 (2.5), 3.3 (2.9), 2.9 (3.0) and 3.6 (3.0) days/week at baseline and months 6 (p<0.0001), 12 (p<0.0001), and 24 (p=0.0267), respectively. PS discontinuation increased over time to 34.4%, 46.7% and 65.2% at 3, 6, and 12 months, respectively. The sensitivity analysis demonstrated similar rates of PS use and discontinuation. Conclusion In this real-world study of adults with SBS-IF, including >50% with IBD, TED was associated with PS reductions comparable to those achieved in clinical trials and higher PS discontinuation rates even when using a conservative analysis approach. Future research will be required to determine individual predictive factors of PS discontinuation.
8
Kounaves, Samuel P., and David Daojing Lu. "Acquisition, processing, and presentation of 3-D chromatovoltammographic data using an IBM PS/2 and par model 273 potentiostat." Computers & Chemistry 16, no. 1 (January 1992): 29–33. http://dx.doi.org/10.1016/0097-8485(92)85005-j.
Full text
9
Eldridge, B., K. Gruben, D. LaRose, J. Funda, S. Gomory, J. Karidis, G. McVicker, R. Taylor, and J. Anderson. "A remote center of motion robotic arm for computer assisted surgery." Robotica 14, no. 1 (January 1996): 103–9. http://dx.doi.org/10.1017/s0263574700018981.
Full textAbstract:
SummaryWe have designed a robotic arm based on a double parallel four bar linkage to act as an assistant in minimally invasive surgical procedures. The remote center of motion (RCM) geometry of the robot arm kinematically constraints the robot motion such that minimal translation of an instrument held by the robot takes place at the entry portal into the patientApos;s body. In addition to the two rotational degrees of freedom comprising the RCM arm, distal translation and rotation are provided to manoeuver the instrument within the patient's body about an axis coincident with the RCM. An XYZ translation stage located proximal to the RCM arm provides positioning capability to establish the RCM location relative to the patients anatomy. An electronics set capable of controlling the system, as well as performing a series of safety checks to verify correct system operation, has also been designed and constructed. The robot is capable of precise positional motion. Repeatability in the ±10 micron range is demonstrated. The complete robotic system consists of the robot hardware and an IBM PC-AT based servo controller connected via a custom shared memory link to a host IBM PS/2. For laparoscopic applications, the PS/2 includes an image capture board to capture and process video camera images. A camera rotation stage has also been designed for this application. We have successfully demonstrated this system as an assistant in a laparoscopic cholecystectomy. Further applications for this system involving active tissue manipulation are under development.
10
Segalowitz, Sidney J., and Roger E. Graves. "Suitability of the IBM XT, AT, and PS/2 keyboard, mouse, and game port as response devices in reaction time paradigms." Behavior Research Methods, Instruments, & Computers 22, no. 3 (May 1990): 283–89. http://dx.doi.org/10.3758/bf03209817.
Full text
11
Areshchankau, I. S. "Development of the learning game environment "Bukashka" ("Ladyb ug") Using client web technologies." Informatics in school, no. 6 (September 25, 2021): 32–38. http://dx.doi.org/10.32517/2221-1993-2021-20-6-32-38.
Full textAbstract:
The theme "Algorithmization and programming" is one of the most difficult in the school informatics course. The computer programs that implement models of microworlds in which virtual actors operate help to explain the basic concepts of this theme for schoolchildren.The best visualization can be achieved using learning environments with drawing actors. The learning environment "Kangaroo Ru" provides the most simple model. It was developed in the early 1990s as a part of an educational project for IBM PS/2 computers running the DOS operating system.The usage of "Kangaroo Ru" is fraught with difficulties on modern computers. This article describes a case of the learning environment that is "Kangaroo Ru" compatible, but is implemented using web technologies HTML, CSS and JavaScript. It is runnable in web browsers of a wide range of hardware platforms.
12
Graves, Roger E., and Ron Bradley. "Millisecond timing on the IBM PC/XT/AT and PS/2: A review of the options and corrections for the Graves and Bradley algorithm." Behavior Research Methods, Instruments, & Computers 23, no. 3 (September 1991): 377–79. http://dx.doi.org/10.3758/bf03203400.
Full text
13
Demianyshyna, V. V. "Clinical course of cystic fibrosis in children." Reports of Vinnytsia National Medical University 24, no. 2 (December 13, 2020): 227–31. http://dx.doi.org/10.31393/reports-vnmedical-2020-24(2)-05.
Full textAbstract:
Annotation. This study is devoted to evaluation of clinical course of cystic fibrosis (CF) in children. The study involved 84 children who were diagnosed with cystic fibrosis. All participants were asked about complaints, life history, physical examination was made, and the results of objective testing and instrumental examination were assessed. The statistical system “IBM SPSS Statistics” version 12 (20) was used using parametric and non-parametric methods of descriptive statistics. Student's criterion was used to assess the significance of the difference between the independent samples, and the Fisher's factor was used for the percentage data. It was shown that 86.91% of subjects had severe or moderate course of CF. Major mutation of CFRT gene F508del/F508del was found in 45.2% children. Common complaints were productive cough (92.9%; р<0.01), failure to thrive (61.9%; р<0.01) and shortness of breath during exercise (40.5%; р<0.01). Results of bacteriologic test of sputum showed significant prevalence of St. aureus (54.0%; р<0.01) and Ps. aeruginosa (38.10%; р<0.01). Patients with severe course of CF had lower rates of FVC, FEV1, PEF, FEF 25%, FEF 50%, FEF 75% than children with moderate and mild course. At the age of 3 years, the diagnosis of cystic fibrosis was established in time by only 76.92% of respondents, which aims to further efforts to improve the quality of its diagnosis.
14
Rousseau, Richard M. "Concepts of Influence Coefficients in XRF Analysis and Calibration." Advances in X-ray Analysis 32 (1988): 77–82. http://dx.doi.org/10.1154/s0376030800020322.
Full textAbstract:
AbstractA new computer program, named CiROU, has been written to determine the chemical composition of homogeneous samples analyzed by X-ray fluorescence spectrometry (XRF). It uses the furdamental algorithm to convert measured intensities into concentrations anc to correct for matrix effects and runs on any IBM-PC/XT/AT, PS/2 or compatible corrputer.The program is very easy to use mainly because it is a step-by-step guide to the routine process of analyzing specimens by XRF and because a user friendly interface makes up a main menu bar containing six major options, which provide several other options inside a pull-down window system.The program is applicable to specimens of any composition with the utmost accuracy that can be obtained from the fundamental-parameters method. It’s unique calibration procedure still adds to the accuracy by eliminating the bias between theory and reality.The program is a complete “off-line” program allowing to perform all the steps of an XRF analysis: calculation of theoretical influence coefficients, calibration, reading of measured intensities, calculation of net intensities and concentrations of unknowns, print-out of analytical reports and data transmission to or from an external computer.
15
Haussmann, Robert E. "Tachistoscopic presentation and millisecond timing on the IBM PC/XT/AT and PS/2: A Turbo Pascal unit to provide general-purpose routines for CGA, Hercules, EGA, and VGA monitors." Behavior Research Methods, Instruments, & Computers 24, no. 2 (June 1992): 303–10. http://dx.doi.org/10.3758/bf03203511.
Full text
16
Gabe, E. J., Y. Le Page, J. P. Charland, F. L. Lee, and P. S. White. "NRCVAX – an interactive program system for structure analysis." Journal of Applied Crystallography 22, no. 4 (August 1, 1989): 384–87. http://dx.doi.org/10.1107/s0021889889003201.
Full textAbstract:
NRCVAX is a complete system of programs, covering all aspects of crystal structure analysis from data reduction to the presentation of results. The system, which is written in a `neutral' Fortran 77, presently exists in two forms. The first runs on a VAX computer under VMS, on an 80386 PC under UNIX and under IBM VM/CMS and MVS/TSO. The second is an adaptation which runs on PC-XT, AT, PS/2 and comparable microcomputers under MS-DOS. The two versions differ somewhat in structure, but very little in code, operation or functionality except for the graphics. The many options of the programs can be selected in a highly interactive manner and because of this the system is very flexible. Most options are assigned default values, however, and it is usually safe to run the routines with a minimum of user input using the defaults. The system will accept data from a wide variety of sources and has interface routines for several other systems. Graphics in the VAX/UNIX version are based on the widely available Tektronix 4000 series protocol, while the microcomputer version supports most common display adapters. It is also possible to prepare files for a variety of plotters, dot-matrix printers and laser printers. Source code is distributed and it should not be difficult to adapt the system to any computer with virtual memory and a Fortran 77 compiler.
17
Lopez Andrade, Bernardo, Beatriz Robredo, Francesca Sartori, Inés Herráez, Maria Antonia Duran Pastor, Marta Garcia Recio, Jorge Jose Martinez Serra, et al. "Red Cell Distribution Width (RDW) at Diagnosis Is Associated to Advanced Stage, Worse Response and Poor Prognosis in Hodgkin Lymphoma." Blood 128, no. 22 (December 2, 2016): 5373. http://dx.doi.org/10.1182/blood.v128.22.5373.5373.
Full textAbstract:
Abstract Red cell distribution width (RDW) is an indicator of the variability in the size of circulating erythrocytes (anisocytosis); different conditions can increase the RDW levels; such as hemolysis, ineffective erythropoiesis and blood transfusions. Recently, different studies have shown an association between increased levels of RDW and inflammation in different diseases, being proposed as a surrogate marker of inflammation and astrong predictor of adverse outcome. The proposed mechanism of this association departs from the finding that Inflammatory cytokines like TNFand IL-6 (part of the classic inflammatory cascade), have been found to inhibit erythropoietin-induced erythrocyte maturation, which is reflected in the RDW increase. Hodgkin lymphoma (HL) is a B cell neoplasm which originates in the germinal or post-germinal center B cells and is characterized by the presence of clonal malignantHodgkin/Reed-Sternbergcells (HRS) in an inflammatory background. The presence of autocrine or paracrine cytokines signaling loops drive proliferation and survival of HRS cells, making HL a lymphoma where the inflammatory status is important. We aim to evaluate the prognostic role of RDW levels in HL patients at diagnosis. METHODS We retrospectively evaluated 119 patients with HL homogenously treated in frontline with ABVD from 2001 to 2015 in the Son Espases University Hospital. To avoid selection bias patients were obtained from Pharmacy and Pathology Departments registries. Main clinical and prognostic factors at diagnosis were obtained from medical records. Cheson criteria were used for response assessment. The RDW was collected from the hemogram at diagnosis. The IBM SPSS STADISTICS program was used for all statistical analyses. PFS (time to progression/relapse) and overall survival (OS) (time to death) were measured from the date of ABVD onset, and were estimated according to the Kaplan-Meier method. We performed the comparisons between those interest variables with the log-rank test. A comparison between categorical variables was made with the chi-square of Fisher's exact test, as appropriate. All reported P-values were two-sided, and statistical significance was defined at P<0.05. For selecting cutoff values in RDW we used ROC curves. RESULTS: Main characteristics of patients were as follows: median age was 37 (15-75) years, 61% were males, 13% had ECOG PS>1, 47% advanced III-IV Ann Arbor (AA) stage, 42% B-symptoms and 29% IPS>2 Median RDW was14.1 (11-23.9).Using ROC curves we selected the cutoff 16.6 for relapse/progression event. We evaluated the association of increased RDW with main prognostic factors at diagnosis. RDW >16.6 at diagnosis was associated with a worse ECOG PS, a more advanced AA stage, higher incidence of B symptoms, IPS>2, higher Erythrocyte sedimentation rate (ESR) and unfavorable lymphocyte/monocyte rate (LMR) (Table 1). Patients with RDW>16.6 were associated with worse responses compared to those with RDW≤16.6: 29% versus 6% of stable/progressive disease and lower complete or partial responses: 67% and 5% versus 93% and 1%, respectively (p=0.004). Univariate survival analysis is shown in Table 2. Age, ECOG PS, AA stage, IPS, LMR and RDW were related to PFS. Age, ECOG PS, IPS and LMR were associated with OS. Multivariate analysis showed age>60 years (HR 7.66; p=0.002), RDW>16.6 (HR=3.41; p=0.005) and advanced AA stage (HR=2.55;p=0.044) as independently associated to worse PFS (Figure 1) while only age>60 years (HR=11.5; p<0.001) and ECOG PS>1 (HR=4.15; p=0.008) independently influenced a worse OS. CONCLUSION: Higher RDW at diagnosis was related with more aggressive and advanced disease in HL and lower response rates, probably reflecting a higher inflammatory activity of the lymphoma and its microenvironment. RDW>16.6 was independently associated with a worse PFS. Disclosures No relevant conflicts of interest to declare.
18
Bento, Leyre, Juan Sarmentero, Ana Ortuño, Marta García-Recio, Bernardo Lopez, Jordi Martínez-Serra, Jose Rodriguez, Antonia Sampol, and Antonio Gutierrez. "Red Cell Distribution Width (RDW) at Diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL) Is Associated to Higher Mortality and Worse Overall Survival." Blood 128, no. 22 (December 2, 2016): 5398. http://dx.doi.org/10.1182/blood.v128.22.5398.5398.
Full textAbstract:
Abstract Red cell distribution width (RDW) is an indicator of the variability in the size of circulating erythrocytes (anisocytosis); different conditions can increase the RDW levels; such as hemolysis, ineffective erythropoiesis and blood transfusions. Recently, different studies have shown an association between increased levels of RDW and inflammation in different diseases, being proposed as a surrogate marker of inflammation and a strong predictor of adverse outcome. The proposed mechanism of this association departs from the finding that Inflammatory cytokines like TNFand IL-6 (part of the classic inflammatory cascade), have been found to inhibit erythropoietin-induced erythrocyte maturation, which is reflected in the RDW increase. Some reports have found a relationship between RDW and mortality related to age or several malignant or non-malignant conditions. However, there is no information about the role of RDW in overall survival (OS) of patients with DLBCL. We aim to evaluate the prognostic role of RDW levels in DLBCL patients at diagnosis. METHODS We retrospectively evaluated 83 patients with DLBCL homogenously treated in frontline with R-CHOP from 2002 to 2013 in the Son Espases University Hospital. To avoid selection bias patients were obtained from Pharmacy and Pathology Departments registries. Main clinical and prognostic factors at diagnosis were obtained from medical records. Cheson criteria were used for response assessment. The RDW was collected from the hemogram at diagnosis. The IBM SPSS STADISTICS program was used for all statistical analyses. PFS (time to progression/relapse) and overall survival (OS) (time to death) were measured from the date of ABVD onset, and were estimated according to the Kaplan-Meier method. We performed the comparisons between those interest variables with the log-rank test. A comparison between categorical variables was made with the chi-square of Fisher's exact test, as appropriate. All reported P-values were two-sided, and statistical significance was defined at P<0.05. For selecting cutoff values in RDW we used ROC curves. RESULTS: Main characteristics of patients were as follows: median age was 62 (20-86) years, 24% had ECOG PS>1, 64% advanced III-IV Ann Arbor (AA) stage, 39% B-symptoms, 51% adjusted-International Prognostic Index (a-IPI) and 39% belong to the high risk (3-5) subgroups of R-IPI Median RDW was 14.6 (11.1-21.1). Using ROC curves we selected the cutoff 14.05 for the death event. We evaluated the association of increased RDW with main prognostic factors at diagnosis. RDW >14.05 at diagnosis was associated with a more advanced age, worse ECOG PS, a more advanced AA stage, higher incidence of B symptoms and IPI>2. However, RDW was not related to disease control in terms of response to therapy (p=0.39) or relapse/progression (p=0.21) rates. Inversely, RDW>14.05 was in fact associated to a higher mortality (47%) compared to only 17% in patients with RDW≤14.05 (p=0.008). Median follow-up was 77 (20-137) months. Univariate survival analysis showed age>60 years (p=0.001), ECOG PS>1 (p=0.036), high risk R-IPI (p=0.005), a higher than 15% reduction in relative dose-intensity (RDI) (p=0.026) and RDW>14.05 (p=0.008) were significantly related to worse OS. By contrast, RDW did not significantly influence progression-free survival (p=0.19). CONCLUSIONS: Higher RDW at diagnosis in this series of DLBCL patients was related with older age, worse ECOG PS and more advanced disease but this was not translated into a worse control of disease in terms of only a small non statistically significant impact in response or PFS. By contrast higher RDW was linked to a significantly higher mortality and worse OS possibly related to a higher proinflammatory basal status and comorbidities. Patients with higher RDW may be at risk of reduction in RDI. These findings could justify including RDW in scores of comorbidities in DLBCL as well as in other malignant and non-malignant conditions. Disclosures No relevant conflicts of interest to declare.
19
Tewari, Sanjay, John Gibson, Stephan Menzel, Anke Hannemann, Swee Lay Thein, Bukola T. Gbotosho, Halima W. M. Al Balushi, and David C. Rees. "Red Cell Transport Abnormalities As Predictors of the Development of Renal Disease in Children with Sickle Cell Disease." Blood 128, no. 22 (December 2, 2016): 1317. http://dx.doi.org/10.1182/blood.v128.22.1317.1317.
Full textAbstract:
Abstract Background: Patients with sickle cell disease (SCD) have the abnormal haemoglobin (Hb) HbS in their red blood cells (RBCs). The complications of SCD may be extensive but are markedly variable between patients. Renal damage (sometimes called sickle cell nephropathy, SCN) is a common finding in about a third of children with SCD, a significant number of whom will proceed to renal failure. As yet, it is not possible to predict which children will develop SCN and who would therefore benefit from earlier and aggressive management. Various biomarkers have been investigated but none have proved efficacious. Changes in RBC membrane permeability are closely linked with polymerisation of HbS and, as such, may represent an important early event in pathogenesis. We postulated that certain RBC characteristics (sickling, K+ transport, PS exposure), which may be inherited independently of the HbS mutation, may correlate with renal pathology, but more importantly, may be identifiable in advance of damage, thereby providing prognostic markers to inform patient management. Participants and Methods: Children (>4 years old) with sickle cell anaemia (SCA) were recruited from the paediatric haematology clinic at King's College Hospital in South London, UK. Patients who had received blood transfusion in the preceding four months or who were on medications known to directly alter RBC cation transport (e.g. dipyridamole and Ca2+ channel blockers) were excluded. Patients on hydroxyurea were included. All patients were in steady state, with no acute symptoms requiring treatment for at least seven days. Clinical and laboratory parameters were collected prospectively at routine clinical attendance. Details of enuresis were collected using specifically developed proforma and patients were divided into two groups: those who stopped wetting their bed before the age of five years and those who were still enuretic after five years of age. RBC permeability was assessed using 86Rb+ as a congener for K+ to measure the activity of main cation transport systems involved in RBC dehydration. The activity of RBC transport pathways and percentage of sickling was measured at 100mmHg, 35mmHg, 15mmHg and 0mmHg. Statistical analysis was conducted using IBM-SPSS, New York. Results: 112 patients of HbSS genotype (SCA) consented to take part in the study. Their clinical profile is summarised Table 1. The percentage of children with enuresis, hypertension and significant albuminuria is shown in Table 2. There was significant correlation between activity of Gardos channel at O2 tensions of 35mmHg, 15mmHg and 0mmHg and enuresis after the age of five years. Psickle activity also showed significant correlation but only in fully deoxygenated RBCs (O2 of 0mmHg.) Table 3. Conclusion In conclusion, the present findings emphasise the significance of a thorough appreciation of RBC permeability to the pathogenesis of SCD. Whilst preliminary, these findings are exciting because they show that the activity of a particular transport pathways, abnormally elevated in SCA patients, are associated with enuresis. These findings suggest that the early identification of increased Gardos and Psickle activity may identify children who would benefit from early treatment for nocturnal enuresis. Disclosures No relevant conflicts of interest to declare.
20
Inami, Masahiro. "Dignāga’s Theory of pakṣābhāsa Reconsidered: How should PS III 2b2–d1 be interpreted?" Journal of Indian and Buddhist Studies (Indogaku Bukkyogaku Kenkyu) 69, no. 2 (March 25, 2021): 854–48. http://dx.doi.org/10.4259/ibk.69.2_854.
Full text
21
Kiel, L. Douglas. "Software Reviews : Putting the One Minute Manager to Work, Version 1 Publisher: Spinnaker Software Corp., One Kendall Sq., Cambridge, MA 02139 (telephone: 617-494-1200) Year of Publication: 1986 Materials: Two 5.25-inch disks (not copy protected), one 3.5-inch disk (not copy protected), 24-page manual Price: $99.95 Machine Specificity: IBM PC/XT/AT, Compaq, Tandy 1000, compatibles: IBM PS/2 series; Tandy 3000 System Requirements: Two 5.25-inch drives, 128K, MS DOS 2.1 or higher; or one 3.5-inch drive, 256K, MS DOS 2.1 or higher Effectiveness: Good User-Friendliness: Excellent Documentation: Good." Social Science Computer Review 7, no. 1 (April 1989): 109–11. http://dx.doi.org/10.1177/089443938900700117.
Full text
22
Lyons, P., N. Noor, J. C. Lee, E. F. McKinney, M. Parkes, and K. G. C. Smith. "P256 Anti-glycan antibody seropositivity at diagnosis does not predict future disease course in patients with Crohn’s disease." Journal of Crohn's and Colitis 14, Supplement_1 (January 2020): S278. http://dx.doi.org/10.1093/ecco-jcc/jjz203.385.
Full textAbstract:
Abstract Background Biomarkers predictive of a patient’s future disease course are critical for personalised medicine. There are two Crohn’s disease (CD) assays with validated associations to a clinical outcome; seropositivity for anti-glycan antibodies (AGAs, Glycominds) and a transcriptional signature of T-cell exhaustion (PredictSURE-IBD™, PS-IBD). The optimal time to use these tests would be at diagnosis before bowel damage occurs. As AGAs have primarily been measured in patients after therapy it’s unclear if they provide prognostic information at diagnosis. To address this we performed a head-to-head comparison of both tests in newly diagnosed CD patients. Methods We recruited 74 CD patients with active disease; all patients gave written informed consent and were managed using an accelerated step-up strategy in accordance with international guidelines. Active disease was confirmed by one or more objective marker (raised CRP/calprotectin or endoscopic review) and active symptoms. AGA seropositivity was measured at Addenbrooke’s with the IBDX panel (Glycominds) according to manufacturer’s instructions. Patient stratification was also performed using the PS-IBDtest (PredictImmune Ltd) according to manufacturer’s instructions. Results Most (80%–59/74) patients were newly diagnosed; 58% (43/74) were seropositive for at least 1 AGA, 19% (14/74) were positive for ≥2 AGAs. Newly diagnosed patients had fewer AGAs (51%, 30/59) than previously diagnosed (87%, 13/15) patients (p = 0.018). We stratified patients into two groups based on seropositivity for 2 or more AGAs—associated with an increased risk of more severe disease but found no significant difference in time to, or frequency of, treatment escalation between the groups. Stratification of patients into IBDhi and IBDlo groups with PS-IBDrevealed a significant difference in the subsequent disease course with IBDhi patients experiencing more aggressive disease, characterised by a shorter time to treatment escalation compared with IBDlo patients (p = 0.001). Conclusion AGA seropositivity at diagnosis (as assessed using the IBDX antibody panel) did not predict the need to escalate treatment due to frequently-relapsing or chronically-active disease. Lower AGA seropositivity in newly diagnosed patients compared with those with previous diagnoses suggested that the extent of antibody positivity is a function of disease duration. Previously reported associations between AGA positivity and disease outcome may, therefore, reflect retrospective aggressive disease course and are unlikely to be useful for informing treatment decisions in newly diagnosed patients. The PS-IBD test result correlated with subsequent disease course indicating suitability for early prediction of clinical outcome.
23
Perry, John R. "Farsi: The Persian Language Learning System, by G.H. “Saeed” Daryanavardan and Fereshteh H. Haeri-Daryanavardan. Version 1.1, Contains licensed program material of Metagraphics Software Inc., 1986. 22 page user manual; Writer/Editor, Gretchen M. Gillen. 5.25″ and 3.5″ diskette for IBM PC/XT/AT or PS/2 and 100% compatibles with 512K RAM and color graphics (CGA/EGA/VGA). Darya International Software, Bethesda MD, 1989. $89." Middle East Studies Association Bulletin 26, no. 2 (December 1992): 272–73. http://dx.doi.org/10.1017/s0026318400026389.
Full text
24
Lodge, Peter. "Software Reviews : Socterms Publisher: Conduit, University of Iowa, Oakdale Campus, Iowa City, IA 52242 (telephone: 319-335-4100) Year of Publication: 1988 Materials: Instructor's notes (19 pages), two 5.25-inch double-sided double-density diskettes (one original and one backup), supplementary materials containing installation directions Price: Single copy, $60; educator packs: 6 copies, $120; 15 copies, $200, 25 copies, $300 (student copy available in the near future for schools that buy SOCTERMS, $15-$20) Machine Specificity: IBM PC, PC-XT, PCJR with extended memory option; IBM PS/2 models 25, 30, 50, 60; true compatibles System Requirements: IBM DOS 2.10-3.20, one 5.25-inch double-sided floppy diskette drive, 192K RAM, color graphics (CGA, EGA) or monochrome adapter and monitor Effectiveness: Good User-Friendliness: Excellent Documentation: Excellent." Social Science Computer Review 7, no. 1 (April 1989): 111–13. http://dx.doi.org/10.1177/089443938900700118.
Full text
25
Fernandes, Lucas Eduardo, Willian Gabriel dos Santos, Fernando Cesar Carducci, Inês Cristina de Batista Fonseca, Lucas Mateus Rivero Rodrigues, Luís Otávio Saggion Beriam, Carlos Theodoro Motta Pereira, Luciana Harumi Shigueoka, and Gustavo Hiroshi Sera. "Resistance of Arabica coffee cultivars to leaf wounds and Pseudomonas syringae under field conditions." January 2020, no. 14(01) 2020 (January 20, 2020): 46–50. http://dx.doi.org/10.21475/ajcs.20.14.01.p1781.
Full textAbstract:
The aims of this study were: (a) to evaluate the resistance of coffee cultivars to Pseudomonas syringae (PS); (b) verify if there are coffee genotypes that present less wounds on the leaves; (c) to study the correlation between amount of wounds and PS severity. The field trial was installed in April 2014 at the IAPAR’s experimental station (Londrina, Paraná, Brazil). 18 Arabica coffee cultivars were evaluated. The cultivars Mundo Novo IAC 376-4 and Catuaí Vermelho IAC 81 were the susceptible controls and IPR 102 was the resistant control. After 32 months of planting the field trial, resistance to PS was evaluated in December 2016. The evaluation of the PS severity was carried out under conditions of natural infections of P. syringae pv. garcae and P. syringae pv. tabaci based on the symptoms, using a grading scale from 1 to 5. The number of wounds on the leaves of the eight cultivars were counted. The results showed that IPR 102 was resistant to Pseudomonas syringae, whereas IPR 99, Arara, IPR 107, Acauã, Sabiá, Catucaiam 24137, Japy and Catuaí Vermelho IAC 81 were susceptible. Mundo Novo and Catucaí Amarelo 2SL were more susceptible than Catuaí Vermelho. IPR 106, Japiam, Catiguá MG 2, Catiguá MG 1 and IBC Palma 2 showed moderate resistance, while IPR 103 and Catucaiam 2015479 were moderately susceptible. The cultivars IPR 102 and IPR 106 presented resistance to wounding because they had lower wounds than other cultivars. Increased leaf wounds was associated with increased P. syringae severity.
26
Tsubamoto, H., R. Wada, R. Kanazawa, S. Komori, H. Maeda, S. Hirota, and S. Adachi. "Neoadjuvant transarterial chemoembolization (TACE) using cisplatin with the combination of dose-dense intravenous administration of paclitaxel for the locally advanced cervical adenocarcinoma." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e16518-e16518. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e16518.
Full textAbstract:
e16518 Background: Adenocarcinoma (including adenosquamous carcinoma) of the uterine cervix has a tendency to early lymph node metastasis and is resistant to radiation therapy, thus results in poor prognosis compared with squamous cell carcinoma. Neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) for bulky cervical adenocarcinoma seems to be an alternative therapy to primary radiation. Methods: P2 at the single institution. Eligible criteria were as follows: Histologically diagnosed cervical adeno or adenosquamous carcinoma with FIGO stage IB2-IVA, Age < or equal to 75, PS 0–2, given informed consent. The NAC regimen consisted of paclitaxel (60mg/m2, iv, D1, D8, D15) and cisplatin (70 mg/m2, trans-uterine arterial infusion followed by embolization using the gelform, D2) repeated every 3 weeks for 2–3 cycles, followed by RH. Primary endpoints were clinical and pathological responses, and secondary endpoints were toxicities, relapse free survival (RFS) and overall survival (OS). Results: Enrolled patients: 22 (1998–2006), Age: median 51 (33–75), FIGO stage: IB2 (9), IIA-IIB (8), IIIB (3), IVA (2), adeno/adenosquamous: 16/6. Toxicities during NAC (CTCAE ver.3) were as follows: G3/G4 neutropenia 18% (4/22), G3/G4 anemia 14% (3/22), G3/G4 thrombocytopenia 0%, G2/G3 sensory neuropathy 0 %, G3/G4 creatinine elevation 0%, G2 alopecia 100%. Clinical response rate (RR: CR+PR) of the patients with stage IB2-IIB was 100%. 16 of 17 received RH, and no residual malignant cells were found pathologically (pCR) in 3. RR of the patients with stage IIIb-IVa was 80%, three patients completed RH with either modified anterior or posterior exenteration, and pCR was found in one patient. The rate of radiation therapy following either NAC or surgery among enrolled patients were 18% (3/17) with stage IB2-IIB and 40% (2/5) with IIIB-IVA. 5 year RFS/OS were 69%/68% with stage IB2-IIb and 60%/60% with stage IIIb-IVa. All 15 alive patients had RH. One patient with stage IVa had urostomy, and other 14 patients have no trouble in urination function. Conclusions: TACE with cisplatin and dose dense paclitaxel in the neoadjuvant setting is feasible and effective for cervical adenocarcinoma. [Table: see text]
27
Korsakova, Yu L., T. V. Korotaeva, E. Yu Loginova, E. E. Gubar, E. A. Vasilenko, A. A. Vasilenko, N. A. Kuznetsova, I. M. Patrikeeva, and E. L. Nasonov. "The prevalence of comorbid and concomitant diseases in psoriatic arthritis patients, data from Russian register." Rheumatology Science and Practice 59, no. 3 (July 15, 2021): 275–81. http://dx.doi.org/10.47360/1995-4484-2021-275-281.
Full textAbstract:
Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis associated with psoriasis (Ps); it belongs to the group of spondyloarthritis and is accompanied by damage to both the spine and peripheral joints, as well as the development of enteritis and dactylitis. In addition to skin and joint damage, PsA has numerous comorbid conditions that are pathogenetically related to the underlying disease, such as inflammatory bowel disease (IBD) and autoimmune eye disease, as well as cardiovascular diseases, obesity and metabolic syndrome, diabetes, osteoporosis, malignancies, mental disorders, and various concomitant diseases. We present data of the prevalence of these pathological conditions among the cohort of PsA patients included in the Russian register.Objective – to study the prevalence of comorbid and concomitant diseases in PsA patients.Materials and methods. The Russian multicenter, observational study with retrospective and prospective data collection of PsA patients included 614 patients with the established diagnosis psoriatic arthritis, corresponding to the CASPAR criteria, from 39 subjects of the Russian Federation, female/male – 331 (54%)/283 (46%). The average age was 45.2±0.52 years, duration of PsA – 5.7±0.27 years, Ps – 15.71±0.56. Duration of observation period: January 2016 – November 26, 2019. The diagnosis of comorbid and concomitant diseases was confirmed by medical specialists in accordance with the ICD-10 code. The analysis of the frequency and structure (%) of these diseases was carried out.Results. The majority of PsA patients had limited Ps: the area of Ps skin lesion (BSA, Basic Surface Area) was less than 3% in 372 (61.5%) patients, BSA from 3% to 10% – in 185 (30.6%), BSA>10% – in 47 (7.8%). Comorbid and concomitant diseases were detected in 297 (48%) of 614 patients. 183 (61.6%) patients had 2 or more diseases in addition to Ps and PsA. Diseases of the circulatory system were detected in 229 (77.1%) PsA patients with comorbid and concomitant diseases (arterial hypertension – in 194 (65.3%), coronary heart disease – in 22 (7.4%)). Diseases of the endocrine system, metabolic disorders were detected in 156 (52.5%) patients with PsA (diabetes mellitus in 44 (14.8%), hyperlipidemia in 44 (14.8%), metabolic syndrome in 36 (12.1%), obesity in 7 (2.4%), and others). Gastrointestinal diseases were observed in 62 (20.9%) patients. Diseases of the biliary system – in 33 (11.1%) patients. Diseases of the musculoskeletal system and connective tissue that are not associated with PsA – in 44 (14.8%). Diseases of the genitourinary system – in 23 (7.7%) patients. Respiratory diseases – in 17 (5.7%) patients. Infectious diseases – in 11 (3.7%). Eye diseases were detected – in 10 (3.4%) patients. Hematological diseases were diagnosed in 6 (2.0%) patients. Depression – in 4 (1.3%) patients.Conclusions. Among 297 patients with PsA with comorbid and concomitant diseases, diseases of the circulatory system are the most common (in 77.1%), less often – diseases of the endocrine system, metabolic disorders (in 52.5%) and diseases of the digestive system (in 32%). Uveitis (2.7%), IBD (1.3%), and depression (1.3%) were rarely detected in our cohort. The majority of patients in the Russian registry had mild forms of Ps (61.5%), and severe Ps (BSA>10%) was observed only in 7.8%. Thus, PsA is associated with a high prevalence of comorbid and concomitant diseases, especially cardiovascular. When choosing a treatment, these diseases should be taken into account. In connection with the new possibilities of therapy, it is necessary to evaluate the potential impact of therapy on patients with comorbid and concomitant diseases in real clinical practice.
28
Карпова, М. Н., Л. В. Кузнецова, Н. Ю. Клишина, and М. Л. Кукушкин. "Effect of ipidacrine on acute pain and development of neuropathic pain syndrome in wistar rats." ZHurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia», no. 2() (May 27, 2019): 29–33. http://dx.doi.org/10.25557/0031-2991.2019.02.29-33.
Full textAbstract:
Цель исследования - изучение особенностей действия ипидакрина («Ипигрикс» Эйч Би Эм Фарма с.р.о., Словакия) на острую боль и динамику развития невропатического болевого синдрома у крыс линии Вистар. Методика. Проведено 2 серии опытов. В 1-й серии влияние ипидакрина изучали на моделях острой боли. Пороги болевой чувствительности определяли до внутримышечного введения ипидакрина (0,5 и 1 мг/кг), а также через 30 и 60 мин после введения. Оценку изменения индивидуальной болевой чувствительности у животных проводили с помощью 2 стандартных тестов: «Tail flick» и «Hot plate». Во 2-й серии изучали влияние ипидакрина на развитие невропатического болевого синдрома, который воспроизводили перерезкой опытным и контрольным животным левого седалищного нерва на уровне подколенной ямки. Интенсивность невропатического болевого синдрома у животных оценивали в баллах по выраженности аутотомии на оперированной конечности, времени появления аутотомий и количеству животных с аутотомией. Внутримышечное введение ипидакрина осуществляли ежедневно (1 мг/кг) в течение 20 сут. Результаты. Введение ипидакрина (0,5 мг/кг) не оказывает антиноцицептивного действия: порог болевой чувствительности не менялся по тестам «Tail flick» и «Hot рlate». Введение ипидакрина (1 мг/кг) за 30 мин до тестирования также не влияло на порог болевой чувствительности по тестам «Tail flick» и «Hot рlate», а через 60 мин после введения ипидакрина порог болевой чувствительности увеличился на 15,8 % (*р=0,033) по тесту «Tail flick» по сравнению с показателем до введения препарата. Заключение. Ипидакрин значительно задерживал развитие невропатического болевого синдрома НБС, но не оказывал влияния на острую боль в тестах «Tail flick» и «Hot plate». The aim of the study was to elucidate specific features of the effect of ipidacrine (IPIGRIKS, Slovakia) оn acute pain and development of neuropathic pain syndrome (NPS) in Wistar rats. Methods. Two series of experiments were performed. In the first series, effects of ipidacrine were studied on models of acute pain. Thresholds of pain sensitivity (PS) were determined before and 30 and 60 min after ipidacrine injection (0.5 and 1 mg/kg, i.m.). Changes in individual pain sensitivity were assessed with two standard tests, tail flick and hot plate. In the second series of experiments, the effect of ipidacrine on the development of NPS was studied. NPS was induced by transection of the left sciatic nerve at the level of popliteal fossa in experimental and control animals. The NPS intensity was evaluated in scores based on severity of autotomy on the operated extremity, time of autotomy emergence, and number of animals with autotomy. Ipidacrine (1 mg/kg, i.m.) was injected daily for 21 days. Results. Ipidacrine at a dose of 0.5 mg/kg did not exert an antinociceptive effect - the PS threshold did not change in the tail flick and hot plate tests. Ipidacrine at a dose of 1 mg/kg 30 min before testing did not affect the PS thresholds in the tail flick and hot plate tests; at 60 min after the ipidacrine injection, the PS thresholds increased by 15.8% (*p = 0.033) in the tail flick test compared to the value before the ipidacrine injection. Conclusion. Ipidacrine significantly delayed the development of NPS but did not affect acute pain in the tail flick and hot plate tests.
29
Zhang, Cong, Yan Kou, Lili Zou, Hui Liang, Li Hou, Tao Li, Yan Zhang, et al. "Phosphatidylserine-Exposing, Tumor-Derived Microparticles Enhance Procoagulant Activity of Platelets and Endothelial Cells after Neo-Adjuvant Chemotherapy in Invasive Breast Cancer." Blood 132, Supplement 1 (November 29, 2018): 2422. http://dx.doi.org/10.1182/blood-2018-99-114901.
Full textAbstract:
Abstract Introduction:Breast cancer is the most common cancer in Chinese women, with invasive breast cancer (IBC) accounting for more than 80% of these diagnoses. Recent studies have shown that increased arterial and venous thromboses occur in IBC and may predict poor prognosis. Uncontrolled activation of coagulation cascade is epidemic in cancer treated with neo-adjuvant chemotherapy (NAC), contributing to hypercoagulability resulting in venous thromboembolism and leading to significant morbidity and mortality. Microparticles (MPs) contribute to coagulation and thrombogenesis. However, the role of tumor-derived microparticles (TMPs) in coagulation during NAC is not fully understood, including clearance of TMPs and their effect on activated platelets and endothelial cells (ECs). Previous studies have shown that elevated circulating MPs has clinical significance in patient prognosis. However, the changes in TMP count, morphology and procoagulant activity (PCA) after NAC in IBC are unclear. This study aimed to explore the properties of MPs derived from breast cancer cells (BCMPs) following exposure to high- or low- dose chemotherapeutic agents and evaluate thrombogenic effects of these BCMPs on platelets and ECs. Methods:BCMPs and MPs were isolated from the blood samples of 25 breast cancer patients treated by NAC and from 20 healthy women (control). Blood samples were taken before and after NAC. MPs were characterized by cell origin and thrombogenicity. In vitro, BCMPs were isolated from BC cell line (high-metastatic MDA-MB-231), pre-exposed to serum-free medium (control), with or without increasing doses of doxorubicin. BCMPs' structure and size were studied using scanning electron microscope (SEM) and Transmission electron microscope. Antigen levels were measured by fluorescence-activated cell sorting. For inhibition assays, isolated BCMPs were pre-treated with lactadherin or anti-TF. Platelets isolated from healthy subjects were treated with BCMPs of different concentrations for 6 h in vitro. Coagulation time, fibrin formation, as well as intrinsic/extrinsic FXa and thrombin were evaluated. BCMPs effects on ECs thrombogenicity were assessed using confocal microscopy, SEM, intrinsic/extrinsic FXa and prothrombinase assays. Results: We observed the PCA of patients 1, 2 and 6 days after NAC. Changes in MPs expression of BC marker, MUC1, were found in patient subgroups. BCMPs were significantly higher at day 1 and 2 compared to before NAC, and reduced at day 6. Similarly, we found that clotting time of whole blood was significantly shortened at day 1, more so on day 2, and was nearly restored on day 6. In vitro, culture of MDA-MB-231 cells in serum-free medium resulted in BCMPs shedding that further increased with the addition of low- or high- dose doxorubicin (Figure A). Phosphatidylserine (PS) levels were similarly higher in BCMPs compared with their parental MDA-MB-231 cells. BCMPs derived from MDA-MB-231 cells stimulated with high-dose doxorubicin demonstrated markedly elevated levels of PS. Lactadherin can reduce the PCA of BCMPs by 72%. These BCMPs enhance EC thrombogenicity and induce platelet activation or even apoptosis, leading to the high PCA (Figure B-D). Data showed that compared with those treated by PBS-derived BCMPs, ECs incubated with doxorubicin-derived BCMPs increased production of intrinsic and extrinsic FXa complexes and thrombin generation. Using confocal microscopy, a significant co-localized fraction of bound FVa and FXa was observed, indicating that ECs treated with BCMPs were able to offer a biological surface for binding coagulation factors, most likely through externalized PS. Conclusions: We made four significant observations. (1) The PCA of patients paralleled the release of BCMPs induced by NAC. Moreover, on the second day of NAC treatment, lactadherin significantly inhibited PCA and fibrin generation, while the effect of anti-TF was minimal. (2) BCMPs induce platelet activation or even apoptosis, leading to the high PCA. (3) SEM showed that BCMPs induce the generation of fiber, impact the densities of fiber deposition and promote clot generation in a dose-dependent manner. (4) Isolated BCMPs exerted a strong cytotoxic effect on ECs, converting them to an increased procoagulant phenotype. Circulating PS+BCMPs can reflect and affect thrombogenicity and, therefore, may be used as a biomarker for hypercoagulability states. Disclosures No relevant conflicts of interest to declare.
30
Sukmadjaja, Deden, and Ade Mulyana. "Regenerasi dan Pertumbuhan Beberapa Varietas Tebu (Saccharum officinarum L.) secara In Vitro." Jurnal AgroBiogen 7, no. 2 (October 1, 2011): 106. http://dx.doi.org/10.21082/jbio.v7n2.2011.p106-118.
Full textAbstract:
<p>(Saccharum officinarum L.) through In Vitro Culture.<br />Deden Sukmadjaja and Ade Mulyana. The research was<br />conducted at the Laboratory of Tissue Culture The Biology of<br />Cell and Tissue Researcher Group ICABIOGRAD, Bogor from<br />June to November 2009 to studied growth and regenerations<br />response some varieties of sugarcane through in vitro<br />culture. The research activities have been carried out in<br />three steps, i.e., callus formation, regeneration of shoots and<br />roots regeneration. The type of explants used in the study<br />was in vitro planlet explants of both sugarcane varieties.<br />Seven media formulations were used for the callus induction<br />and regeneration of shoots, while five media formulations<br />were used for the roots regeneration. The results<br />showed that the highest respond for calluses induction was<br />Bulu Lawang varieties at media formulation MS + 2.4-D 2<br />mg.l-1 + BAP 0.4 mg.l-1 + CH 2000 mg.l-1 and PS 951 varieties<br />at media formulation MS + 2.4-D 1 mg.l-1 + BAP 0.4 mg.l-1.<br />While the highest respond for regeneration of shoots was<br />Bulu Lawang varieties at media formulation MS0 (control<br />MS) dan PS 951 varieties at media formulation MS + BAP 1<br />mg.l-1 + kinetin 1 mg.l-1 + NAA 0.5 mg.l-1 + GA3 0.5 mg.l-1.<br />The highest respond of roots regeneration was Bulu Lawang<br />and PS 951 varieties at media formulation MS + IBA 1 mg.l-1.<br />Acclimatization of plantlets produced were grew successfully<br />about 90-100% in greenhouse.</p>
31
Deodhar, A., K. Winthrop, R. Bohn, B. Chan, R. Suruki, J. Stark, H. Yun, S. Siegel, L. Chen, and J. Curtis. "SAT0370 TUMOUR NECROSIS FACTOR INHIBITOR THERAPY DOES NOT REDUCE THE INCIDENCE OF COMORBIDITIES AND EXTRA-ARTICULAR MANIFESTATIONS IN ANKYLOSING SPONDYLITIS: AN ANALYSIS OF THREE US CLAIMS DATABASES." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1132.1–1133. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4201.
Full textAbstract:
Background:Comorbidities and extra-articular manifestations (EAMs) substantially increase disease burden and mortality risk in patients (pts) with ankylosing spondylitis (AS).1,2Tumour necrosis factor inhibitors (TNFi) are highly efficacious and effective in AS treatment (tx), and are used after inadequate response to non-steroidal anti-inflammatory drugs.3,4However, the impact of TNFi on the incidence of comorbidities and EAMs in pts with AS is unknown.5Objectives:To determine the incidence of comorbidities and EAMs in TNFi vs non-TNFi treated pts with AS in the US.Methods:This was a retrospective, observational cohort study using data from 3 healthcare insurance claims databases: Multi-Payer Claims Database (MPCD Optum Insight; 2007–2010), Truven MarketScan®(2010–2014) and US Medicare Fee-for-Service Claims database (2006–2014). Eligible pts: ≥20 years (yrs) for MarketScan/MPCD or ≥65 yrs for Medicare, had an AS diagnosis (≥2 International Classification of Disease, 9thversion [ICD-9] diagnosis codes of 720.0 from a rheumatologist) and ≥12 months’ continuous medical and pharmacy enrolment prior to AS diagnosis (AS index date). Pts with AS not receiving tx were excluded. Tx exposure was reported from the first date of a new prescription/administration of an AS tx (no prior exposure) after the AS index date. Crude incidence rates (IR; shown as cases/100 pt-yrs) were calculated for EAMs (uveitis, psoriasis [PSO], psoriatic arthritis [PsA], inflammatory bowel disease [IBD]), with follow-up until the earliest of: death, lost medical/pharmacy coverage, study period end, first outcome occurrence, tx switch/discontinuation. Hazard ratios (HRs) of comorbidities (hospitalised infection, solid cancers) and EAMs for propensity score (PS)-matched pt groups were calculated using Cox proportional hazard regression models. Pts with the specific comorbidity/EAM of interest prior to AS index date were excluded. PS analyses assessed probability of TNFi initiation vs non-TNFi tx and adjusted for factors including comorbidities and demographics. HRs with confidence intervals crossing 1 are not reported.Results:20,460 pts with AS were eligible (MPCD: 2,384; MarketScan: 9,032; Medicare: 9,044). In all databases, crude IR of EAMs were higher for TNFi vs non-TNFi treated pts (Figure 1). In the PS-matched cohort, incidences of hospitalised infections were lower in TNFi vs non-TNFi treated pts from the MarketScan and Medicare databases (Figure 2). Higher incidences of solid cancers and EAMs were observed in TNFi vs non-TNFi treated pts; Medicare data (Figure 2). A higher risk of PsA and PSO was seen in TNFi vs non-TNFi treated pts; MarketScan data (Figure 2). PS-matched cohort data from the MPCD database were non-significant.Conclusion:Despite strong efficacy in treating AS-related signs and symptoms, similar incidence of comorbidities and increased incidence of some EAMs (IBD, PSO/PsA, uveitis) was seen in TNFi vs non-TNFi treated pts in the PS-matched analyses. This may be due to channelling of pts with more severe AS to receive TNFi, despite the PS-matched analysis aiming to overcome this. Moreover, prior medical history of Medicare pts may not be captured in the database, as pts are typically older with longer disease durations. While these results confirm previous findings,6a prospective observational study is required to generalise to pts outside the US.References:[1]Stolwijk C. Ann Rheum Dis 2015;74:1373–8;[2]Bremander A. Arthritis Care Res 2011;63:550–6;[3]Braun J. Scand J Rheumatol 2005;34:178–90;[4]Ji X. Front Pharmacol 2019;10:1476;[5]Maxwell LJ. Cochrane Database Syst Rev 2015:CD005468;[6]Walsh J. J Pharm Health Serv Res 2018;9:115–21.Acknowledgments:This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.Disclosure of Interests:Atul Deodhar Grant/research support from: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Kevin Winthrop Grant/research support from: Bristol-Myers Squibb, Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, Galapagos, Gilead, GSK, Pfizer Inc, Roche, UCB, Rhonda Bohn Consultant of: UCB Pharma, Benjamin Chan: None declared, Robert Suruki Employee of: UCB Pharma, Jeffrey Stark Employee of: UCB Pharma, Huifeng Yun Grant/research support from: Bristol-Myers Squibb and Pfizer, Sarah Siegel: None declared, Lang Chen: None declared, Jeffrey Curtis Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Corona, Crescendo, Genentech, Janssen, Pfizer, Roche and UCB Pharma, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Corona, Crescendo, Genentech, Janssen, Pfizer, Roche and UCB Pharma
32
Zilembo, Nicoletta, Roberto Buzzoni, Luigi Celio, Cristina Noberasco, Leonardo Ferrari, Alberto Laffranchi, Giovanni Vicario, Stella Dolci, and Emilio Bajetta. "Formestane as Treatment of Advanced Breast Cancer in Elderly Women." Tumori Journal 80, no. 6 (December 1994): 433–37. http://dx.doi.org/10.1177/030089169408000605.
Full textAbstract:
Aims and background The number of elderly people is increasing, and the proportion of breast cancer in female cancer patients older than 65 years is 26%. In elderly patients, hormone therapy is widely accepted as the treatment of choice, because of its efficacy and good tolerability compared to chemotherapy. The aim of this study was to evaluate the endocrinologic and clinical activity of formestane (4-hydroxyandrostenedione), a selective aromatase inhibitor, in elderly patients with advanced breast cancer. Methods Thirty-five patients older than 65 years, selected from a larger group, were given formestane (250 mg or 500 mg i.m. fortnightly). Patients were evaluable for tumor response after 4 doses of formestane. Blood samples were collected to evaluate E2, FSH, LH, SHBG and DHEAS serum levels at baseline and after 2, 4, 8,12 and 24 weeks. Results Thirty patients had PS ≤ 1 (ECOG) and only 5 patients had PS = 2. Twenty-six patients were ER positive. Previous hormonal treatment for metastatic disease had been given to 17 patients; only 1 case had received chemotherapy. The overall response rate was 51% (95% C.I. 35–67%) and the median response duration was 9.5 months. Three complete responses were observed on viscera. The best responses were obtained on soft tissues (59%); on bone and viscera the response was respectively 45% and 47%. Local and systemic tolerability was highly satisfactory. Formestane induced prolonged suppression of E2 levels in all of the patients, and a significant reduction in SHBG levels was also observed from month 2 onward. A statistically significant ( P = 0.0001) rise in serum FSH was also observed during the therapy. Conclusions The study showed that formestane induced a long-lasting suppression of E2 levels and a satisfactory overall response. In our opinion, the drug is an effective and well-tolerated approach in the management of advanced breast cancer in elderly patients.
33
Nadiminti, Kalyan, Abhishek A. Mangaonkar, Kimberly J. Langer, Shakila P. Khan, Vilmarie Rodriguez, Naseema Gangat, Michelle A. Elliott, et al. "Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes." Blood 134, Supplement_1 (November 13, 2019): 3300. http://dx.doi.org/10.1182/blood-2019-121742.
Full textAbstract:
Introduction: Allogeneic stem cell transplant (HCT) is the only potential curative option for patients with inherited marrow failure (iBMF) and myeloid germline predisposition syndromes (GPD). HCT outcomes are influenced by inherent disease specific-nuances such as alkylating agent and radio-sensitivity, immune deregulation, and higher risks for graft failure and GVHD; factors contributing to transplant related mortality (TRM) and morbidity. We carried out this retrospective study to assess survival outcomes and long term complications (LTC) in patients with IBMF and GPD that underwent HCT. Patients and methods: We queried our institutional database and identified patients with iBMF and GPD as defined by the 2016 WHO classification. These included Fanconi anemia (FA), short telomere syndromes (STS), Diamond-Blackfan anemia (DBA), GATA2 and RUNX1 haploinsufficiency, congenital amegakaryocytic thrombocytopenia (CAMT), deficiency of adenosine deaminase 2 (DADA2), among others. Patients with acquired causes of BMF were excluded. Statistical analyses were performed using SAS (JMP v14.1). Results: Twenty eight patients, median age 10 years (1 month-63 years), 46% males, were included in the study (table 1). Fanconi anemia Seven (25%) patients with FA underwent HCT, 5 (71%) without myeloid transformation and 2 after transformation to MDS/AML. Five (71%) patients received a RIC, 4 (57%) prior to transformation. At a median follow up (FU) of 126 m, the median OS was 194 m (95% CI 34m; NR) and 10 year survival was 64%. Grade 1 aGVHD was seen in four (57%) and 3 (42%) developed mild cGVHD, while 1 developed a donor derived AML (sibling not tested for FA). LTC included second primary malignancy (SPM) - squamous cell cancer (SCC) of skin and muscle invasive bladder cancer (MIBC) in 1(14%) and SCC of head/neck and anogenital region in 3 patients (43%), psychosocial complications (PS) in 6(85%), premature ovarian failure (POF) in 3(43%), and avascular necrosis (AVN) in 4(57%) patients. Short Telomere Syndromes (STS) Seven patients with STS underwent HCT, 2 (28%) after transformation to MDS. Five (71%) received RIC, including both the transformed patients. At a median FU of 67m, median OS was NR (95% CI 2m; NR) and 5 year survival was 47%. One (14%) patient developed grade 2 aGVHD and mild cGVHD of skin. Three (43%) developed SPM - skin cancers in 2 and MIBC in 1. PS was noted in 1(15%), and AVN in 3(43%). Three (43%) patients had concomitant mild IPF/restrictive lung disease. GATA2 haploinsufficiency : Seven patients with GATA2 haploinsufficiency underwent HCT; 2(28.5%) after transformation to MDS and 3(43%) to AML, of which 2(40%) received MAC. At a median FU of 57m, median OS was NR (95% CI 7m; NR) and 5 year survival was 71%. Three (50%) developed grade 2 aGVHD of skin and GI tract and 2(33%) developed mild cGVHD. LTC include PTLD, AVN and POF in 1 patient each. Ribosomopathies : One patient (13y) with DBA underwent RIC HCT and developed grade 2 aGVHD, secondary iron overload, and died at 10 months due to severe fungal infection. Others : Identical twins with CAMT underwent HCT (at 4y and 5y) from the same unrelated donor and at last FU (74m and 87m, respectively) remain 100% donor without GVHD. Two children with primary immunodeficiency and marrow failure underwent HCT (at 2y and 7y), one after transformation to MDS. The non-transformed patient is currently alive (120m), while the patient with transformation died 1month after HCT from disseminated cytomegalovirus infection. One patient with germline RUNX1 deletion developed CMML and underwent a RIC HCT and is alive at a FU of 4 months, with no GVHD. One patient with DADA2 (n=1) underwent RIC HCT without LTC. Due to the smaller cohort size, we compared OS in transformed and non-transformed patients for the IBMF and GATA2 patients only (n=24, 9 with transformation) (figure1). At a median FU of 74m, the median OS of transformed vs non-transformed patients was 108m(95% CI 1;108m) and 163m(95% CI 67m; NR), respectively (p=0.033). Conclusions: Our study demonstrates that HCT remains an important intervention for IBMF and GPD, with the maximum impact being gained prior to transformation. While only mild chronic GVHD was noted (37%), inherent syndromic issues resulted in a high rate of SPM (FA/STS) and organ failure (STS- IPF). Notably, one FA patient who received an MRD HCT developed donor derived AML, underlining the importance of genetic screening in asymptomatic related individuals. Disclosures Kenderian: Lentigen: Research Funding; Kite/Gilead: Research Funding; Morphosys: Research Funding; Humanigen: Other: Scientific advisory board , Patents & Royalties, Research Funding; Novartis: Patents & Royalties, Research Funding; Tolero: Research Funding. Patnaik:Stem Line Pharmaceuticals.: Membership on an entity's Board of Directors or advisory committees.
34
Slettjord, Tiril H., Hege J. Sekkenes, Heng Chi, Jarl Bøgwald, Trilochan Swain, Roy A. Dalmo, and Jaya Kumari Swain. "Overexpression of T-bet, GATA-3 and TGF-ß Induces IFN-γ, IL-4/13A, and IL-17A Expression in Atlantic Salmon." Biology 9, no. 4 (April 20, 2020): 82. http://dx.doi.org/10.3390/biology9040082.
Full textAbstract:
The overexpression of GATA-3, T-bet and TGF-ß may theoretically induce IL-4/A, IFN-γ and IL-17A expression, respectively. Whether this also applies to fish is not yet known. The plasmid vectors encoding reporter gene (RFP)-tagged T-bet, GATA-3 and TGF-ß were used as overexpression tools, transfected into cells or injected intramuscularly to monitor the expression of IFN-γ, IL-4/13A and IL-17A. In addition, the fish were either experimentally challenged with Vibrio anguillarum (VA group) or Piscirickettsia salmonis (PS group). The reporter gene (RFP) inserted upstream of the GATA-3, T-bet and TGF-ß genes, was observed in muscle cell nuclei and in inflammatory cells after intramuscular (i.m.) injection. PS group: following the injection of GATA-3 and T-bet-encoding plasmids, the expression of GATA-3 and T-bet was high at the injection site. The spleen expression of IFN-γ, following the injection of a T-bet-encoding plasmid, was significantly higher on day 2. VA group: The T-bet and GATA-3-overexpressing fish expressed high T-bet and GATA-3 mRNA levels in the muscles and on day 4 post-challenge. The expression of TGF-ß in the muscles of fish injected with TGF-ß-encoding plasmids was significantly higher on days 7 (8 days pre-challenge) and 19 (4 days after challenge). The protective effects of the overexpression of T-bet, GATA-3 and TGF-ß on both bacterial infections were negligible.
35
Marinaccio, M., E. De Marino, E. Mele, R. Catacchio, C. Pellegrino, V. Pinto, and S. Schonauer. "Paclitaxel, ifosfamide, and cisplatin regimen as neoadjuvant chemotherapy in young women with locally advanced squamous cervical cancer." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 5587. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.5587.
Full textAbstract:
5587 Background: Chemoradiotherapy is the standard treatment of advanced cervical cancer. Neoadjuvant chemotherapy (NAC) may represent an alternative for locally advanced cervical cancer (LACC).This study was undertaken to evaluate the efficacy of NAC in young patients with squamous LACC. Methods: Since 2000 to 2008, 61 pts (mean age 43 yrs) with squamous LACC were treated with NAC and afterwards evaluated for radical surgery. Eligibility included proven histologically diagnosis of squamous cervical carcinoma, FIGO stage IB2/IIA>4cm/IIB, measurable disease, ECOG PS 0–2, no prior therapy and age under 49 years. All patients received TIP regimen (cisplatin 50 mg/m2 i.v. day 1, paclitaxel 175 mg/m2 over 3 hrs i.v.day1, ifosfamide 5,000 mg/m2 plus mesna 6,000 mg/m2 over 24 hrs i.v. day 1–2). Each cycle was repeated every 21 days. Patients were evaluated 4–6 weeks after the completion of the third cycle with the purpose to perform radical surgery according to clinical response. Results: 35pts (57.4%) were stage IB2; 9 (14.7%) were IIA >4cm; and 17 (27.9%) were IIB. After restaging the clinical results were: CR = 4/61 (6.6%), PR = 51/61 (83.6%); no response = 5/61 (8.2%); progression = 1/61 (1.6%). A total of 55 pts (90.1%) were eligible for surgery; 6/61 pts (9.8%) were submitted to curative radiotherapy (until 2004) or chemoradiotherapy. Pathological responses after surgery were: 4 pCR (7.3%); 46 pPR (83.6%); and 5 (9.1%) pPR with presence of positive surgical margins or metastatic lymph nodes. Out of 55 pts, 50 received 2 cycles of TIP regimen as a consolidation therapy before follow-up; 5 pts with incomplete pPR underwent radio/chemoradiotherapy. After NAC an overall downstaging of LACC was obtained in 50/61 pts (82.0%). In this group of pts at the median follow-up of 42 months (range 4–98) updated as of December 2008, the 3-years progression-free survival and overall survival are 85.9% and 82.0%, respectively. Conclusions: Our results indicate that TIP regimen-based NAC is an attractive option in young women with squamous LACC (IB2,IIA >4cm, IIB) that strongly desire surgery.The rate of patients with a prolonged remission of disease (82.0%) suggests that the clinical benefit of TIP regimen-based NAC followed by surgery may be comparable to chemoradiotherapy. No significant financial relationships to disclose.
36
Masdeu, M., R. M. García-García, P. Millán, L. Revuelta, O. G. Sakr, P. G. Blanco, D. Cortegano, P. L. Lorenzo, and P. G. Rebollar. "188 EFFECT OF RABBIT SEMINAL PLASMA IN OVULATING RESPONSE." Reproduction, Fertility and Development 25, no. 1 (2013): 243. http://dx.doi.org/10.1071/rdv25n1ab188.
Full textAbstract:
The presence of an ovulation-inducing factor (OIF) in the seminal plasma (SP) of several species with spontaneous and induced ovulation, included the rabbit, has been documented. The biochemical identity of OIF in SP remains unknown, but it seems that OIF is a protein (Ratto et al. 2011 Reprod. Biol. Endocrinol. 9, 24). The aim of this study was to determine if the protein present in the rabbit SP could induce ovulation in a dose manner and provoke changes in plasma hormone concentrations [LH and progesterone (P4)]. Semen was collected from 12 male rabbits using an artificial vagina, pooled, centrifugated at 3000g for 30 min twice and analysed by Bradford method to determine protein concentration that was 7 mg protein mL–1 of SP. After storage at –80°C, the SP was lyophilized for use at different concentrations. Twenty-four females were synchronized with an i.m. injection of 25 IU of equine chorionic gonadotropin and randomly assigned to 4 groups (n = 6). Forty-eight hours later (day 0) they were given a single i.m. dose of 1) 1 mL of saline solution (SS; negative control), 2) 20 µg of gonadorelin (GnRH; positive control), 3) 1 mL of lyophilized SP diluted in SS containing 7 mg of protein (SP7), 4) 1 mL of lyophilized SP diluted in SS containing 14 mg of protein (SP14). Blood samples for LH measurement were taken every 30 min from 30 min before injection to 2 h after treatment. Blood samples for P4 measurement were taken every 2 days from Day 0 to Day 6. Hormone determinations were made by enzyme immunoassay. Ovulation rate (OR), number of corpora lutea (CL), follicles higher than 1 mm, and total number of hemorrhagic follicles were determined after euthanasia on Day 7. Statistical analysis was performed by ANOVA. The OR was significantly higher (P < 0.0001) in GnRH than in SS, SP7, and SP14 groups (OR: 100, 0, 0, and 8.3%, respectively). Total number of CL counted in does that ovulated in GnRH and SP14 groups was not different (13.7 ± 0.8 and 9 ± 0.0 CL, respectively; P < 0.0001). No statistical differences were observed between groups on the number of follicles higher than 1 mm (GnRH: 17 ± 2.4; SS: 15 ± 1.6; SP7: 11.7 ± 2.6; SP14: 14.8 ± 0.9) and anovulatory hemorrhagic follicles (GnRH: 2.3 ± 0.9; SS: 0.2 ± 0.2; PS: 1.7 ± 0.8; PS 14: 1.7 ± 1.5). Treatment was followed by a surge in plasma LH concentration beginning 30 min after treatment to 120 min in GnRH group ranging ~75 ng mL–1, whereas in the other groups it remained at basal levels (around 20 ng mL–1; P < 0.0001). Plasma P4 concentrations were significantly increased from Day 2 to 6 (4.7 ± 0.7 to 22.3 ± 3.7 ng mL–1; P < 0.0001) only in rabbits treated with GnRH. Plasma P4 concentrations did not vary throughout the experimental period in all OIF-treated rabbits. The present study failed to demonstrate the effect of 3 different dosages of OIF of the rabbit SP on induction of ovulation. More studies are necessary to elucidate if rabbit SP could induce ovulation in rabbit females. We acknowledge CM and MEC for funding.
37
Oliva, Esther Natalie, Suman Kambhampati, Albert Oriol, Ignazia La Torre, Barry Skikne, C. L. Beach, Keshava Kumar, et al. "CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial." Blood 136, Supplement 1 (November 5, 2020): 14–15. http://dx.doi.org/10.1182/blood-2020-137562.
Full textAbstract:
BACKGROUND: AML is an aggressive malignancy primarily affecting older individuals. Although 40%-60% of patients (pts) aged >60 years attain complete remission (CR) with IC, 80%-90% of them eventually relapse. In the continuum of AML care, the greatest expenditures are associated with relapsed/refractory disease, and hospitalization is the largest component (~70%) of direct AML healthcare costs (Pandya, 2020). In the randomized, phase III QUAZAR AML-001 Maintenance Trial, CC-486, an oral hypomethylating agent, significantly prolonged overall (OS) and relapse-free survival (RFS) vs. placebo (PBO) in pts with newly diagnosed (ND) AML in first remission following IC. OBJECTIVE: Determine rates of hospitalization and days in hospital with CC-486 and PBO in QUAZAR AML-001, and quantify associated costs of hospitalization using unit costs estimated from a US claims database. METHODS: In QUAZAR AML-001, eligible pts were age ≥55 years, with de novo or secondary AML, intermediate- or poor-risk cytogenetics, and ECOG PS ≤3; achieved first CR or CR with incomplete count recovery (CRi) after IC ± consolidation; and were not candidates for hematopoietic stem cell transplant (HSCT). Within 4 months of CR/CRi, pts were randomized 1:1 to CC-486 300 mg or PBO, administered once-daily on days 1-14 of repeated 28-day cycles. Pts who received ≥1 dose of study drug were followed for hospitalizations and durations of stay from date of informed consent through 28 days after last dose. The mean number of days hospitalized per month (30 days) in each treatment arm was computed by dividing the aggregate number of hospitalized days by the number of ongoing pts at each time-point. Rates of hospitalization and days in hospital were also adjusted for duration of CC-486 and PBO exposure. 95% confidence intervals (CI) for relative risk (RR) estimates and associated P values are based on asymptotic methods. Patients with a primary diagnosis of AML, preceded by ≥6 months (baseline) without a claim for AML were identified in the IBM MarketScan Commercial & Medicare database from April 2013 to July 2019. A stepwise procedure was then used to include pts aged ≥55 years at diagnosis, without a diagnosis of another primary cancer or HSCT, and with insurance coverage during the entire 6-month baseline period. Unit cost of hospitalization was derived as the average total AML-related hospitalization costs incurred per day of stay, adjusted for inflation to 2019 US dollars. RESULTS: In all, 469 pts were enrolled in QUAZAR AML-001 and received CC-486 (N=236) or PBO (N=233). Total exposure to CC-486 was 363.8 pt-years (PY) and to PBO was 234.9 PY. In all, 108 pts (45.8%) in the CC-486 arm and 118 (50.6%) in the PBO arm were hospitalized. The total numbers of hospitalizations were 173 in the CC-486 arm and 151 in the PBO arm; however, the exposure-adjusted rate of hospitalization was significantly lower in the CC-486 arm: 0.48/PY vs. 0.64/PY, respectively (RR 0.740 [95%CI 0.595, 0.920]; P = 0.0068) (Table). The total number of days hospitalized was 2872 in the CC-486 arm and 3139 in the PBO arm, and the exposure-adjusted days-in-hospital rate was significantly lower in the CC-486 arm (7.89/PY vs. 13.36/PY in the PBO arm; RR 0.591 [95%CI 0.562, 0.621]; P < 0.0001) (Table). Of the ND-AML cohort identified in the MarketScan database, 3058 pts had ≥ 1 noncapitated hospitalization and provided the basis for estimated hospitalization-related costs. Median age and sex distribution of these pts were generally consistent with those of pts in QUAZAR AML-001. The mean AML-related hospitalization cost incurred in the database was $7,126/day (2019 USD). Thus, based on exposure-adjusted days-in-hospital rates in the CC-486 and PBO arms (7.89/PY and 13.36/PY, respectively), the estimated mean costs of hospitalization in QUAZAR AML-001 were $56,224/PY in the CC-486 arm and $95,201/PY in the PBO arm. Cumulative cost savings in the CC-486 arm compared with PBO ranged from $2,837 in month 2 to $40,909 by month 24 (Figure). CONCLUSION: CC-486 was associated with significantly reduced exposure-adjusted risk of hospitalization and days in hospital compared with PBO, which are estimated to result in substantial cumulative cost savings. Significantly prolonged RFS with CC-486 vs. PBO in this study (10.2 vs. 4.8 months; P = 0.0001) may translate into substantial economic benefits, with lower hospitalization-related costs due to reduced rates of hospitalization and days in hospital. Disclosures Oliva: Alexion: Consultancy; Apellis: Consultancy; Abbvie: Consultancy; Amgen: Consultancy; Novartis: Consultancy; BMS: Consultancy, Honoraria, Patents & Royalties, Speakers Bureau. Oriol:Amgen: Consultancy, Speakers Bureau; Janssen: Consultancy; Sanofi: Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. La Torre:Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Skikne:Bristol Myers Squibb: Current Employment. Beach:Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Kumar:Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Dong:Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Chen:Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Ranjan:SmartAnalyst India Pvt. Ltd.: Current Employment. Kiendrebeogo:SmartAnalyst, Inc.: Current Employment. Braun:Servier: Research Funding; Daiichy-Sankyo: Honoraria.
38
"IBM PS/2 handbook." Choice Reviews Online 26, no. 01 (September 1, 1988): 26–0348. http://dx.doi.org/10.5860/choice.26-0348.
Full text
39
"VDA-Kommunikation mit IBM PS/2: PS/2-DAX-Kommunikationssystem für VDA 4914." Zeitschrift für wirtschaftlichen Fabrikbetrieb 83, no. 5 (May 1, 1988): 233. http://dx.doi.org/10.1515/zwf-1988-830512.
Full text
40
"Hard disk adds 45 MB to IBM PS/2." Computers in Physics 2, no. 1 (1988): 85. http://dx.doi.org/10.1063/1.4822660.
Full text
41
"Interface board does digital I/O with IBM PS/2." Computers in Physics 2, no. 1 (1988): 84. http://dx.doi.org/10.1063/1.4822657.
Full text
42
"PC-Statistics: version 2.1: statistical software for the IBM PC, XT, AT, PS/2 and compatibles." Choice Reviews Online 27, no. 11 (July 1, 1990): 27–6680. http://dx.doi.org/10.5860/choice.27-6680.
Full text
43
Häfner, G., A. Esmaylzadeh, J. Jolie, J. M. Régis, C. Müller-Gatermann, A. Blazhev, C. Fransen, et al. "Lifetime measurements in $$^{182}\hbox {Pt}$$ using $$\gamma $$–$$\gamma $$ fast-timing." European Physical Journal A 57, no. 5 (May 2021). http://dx.doi.org/10.1140/epja/s10050-021-00492-x.
Full textAbstract:
AbstractThe level lifetimes of the $$2_1^+$$ 2 1 + and $$4_1^+$$ 4 1 + states in $$^{182}\hbox {Pt}$$ 182 Pt have been re-measured employing the $$\gamma $$ γ –$$\gamma $$ γ fast-timing technique using fast $$\hbox {LaBr}_3$$ LaBr 3 (Ce) scintillators. Excited states in the nucleus of interest were populated by the fusion-evaporation reaction $$^{170}\hbox {Yb}(^{16}\hbox {O},\hbox {4n})^{182}\hbox {Pt}$$ 170 Yb ( 16 O , 4n ) 182 Pt at a beam energy of 87 MeV provided by the FN Tandem accelerator of the University of Cologne. The lifetime of the $$2_1^+$$ 2 1 + state was re-measured with high accuracy to be $$\tau = 563(12)~$$ τ = 563 ( 12 ) ps and resolves inconsistencies from previous measurements. Experimental results are compared to theoretical calculations in the framework of the sd-IBM with and without configuration mixing.
44
Erwanto, Zulis, Wahyu Naris Wari, and Yuni Ulfiyati. "IbM KELOMPOK PENGGUNA AIR BERSIH DESA PAKEL MELALUI TEKNOLOGI FILTER BETON PASIR." J-Dinamika: Jurnal Pengabdian Masyarakat 1, no. 2 (December 28, 2016). http://dx.doi.org/10.25047/j-dinamika.v1i2.281.
Full textAbstract:
Desa Pakel, Kabupaten Banyuwangi mengalami permasalahan dalam pemenuhan kebutuhan air bersih bagi warganya. Sumber mata air utama yang digunakan oleh warga Desa Pakel terletak di daerah perbukitan dengan konstruksi bangunan penangkap mata air yang sederhana. Lokasi mata air berada di tengah hutan dan terletak di kemiringan bukit menyebabkan air yang tertampung berpeluang mengalami pencemaran dan kandungan sedimen yang tinggi apalagi pada saat musim penghujan. Mitra dalam kegiatan IbM adalah Pengelola kelompok pengguna air minum Desa Pakel Kabupaten Banyuwangi.Sesuai prioritas kebutuhan maka ditawarkan solusi permasalahan yang dihadapi Mitra yakni dengan penyuluhan tentang teknologi penjernihan dan pengolahan air bersih, dan rancang bangun instalasi filter beton pasir. Manfaat yang diperoleh berupa pemahaman tentang pentingnya kesehatan dalam pengolahan air bersih dengan sistem instalasi pengolahan air bersih menggunakan teknologi filter beton pasir.Berdasarkan hasil sosialisasi dan penyuluhan pengolahan air bersih di Desa Pakel tanggal 24 September 2016 di Balai Desa Pakel, pengolahan air bersih dalam upaya pemenuhan kebutuhan air bersih melalui proses penjernihan air dengan instalasi teknologi filter beton pasir yang ditempatkan di dalam reservat. Filter beton pasir merupakan salah satu unit proses dalam instalasi pengolahan air (IPA) yang terbuat dari bahan dari kerikil, pasir beton, arang aktif, dan mortar pasir silica dengan perbandingan 1 PC : 10 PS yang disusun sedemikian rupa untuk menghilangkan kekeruhan air. Berhubung instalasi penempatan filter tersebut di dalam tandon dengan tekanan kecil maka filter beton pasir yang digunakan menggunakan ukuran partikel lebih dari 1-2 mm dengan ketebalan 15 cm agar kuantitas debit airnya tetap sesuai dengan kapasitasnya dan sirkulasinya biar cepat. Bahan yang digunakan sebagai filter terbuat dari pipa PVC Ø 4” dengan ketinggian 50 cm menyesuaikan diameter pipa outlet. Filter terdiri dari 4 tabung pipa. Teknologi filter beton pasir ini merupakan bentuk prototype filter untuk percontohan di Desa Pakel dan bisa dibuat skala rumah tangga di tiap-tiap rumah atau diinstalasi sebelum masuk ke hidran umum.
45
"Glycemic control and awareness among diabetic patients of nutrition recommendations in diabetes." Roczniki Państwowego Zakładu Higieny, 2020, 191–96. http://dx.doi.org/10.32394/rpzh.2020.0116.
Full textAbstract:
Background. The incidence of diabetes has been rising rapidly, especially in urbanized countries. It is estimated that by 2035 the number of diabetics will have increased to almost 600 million around the world. There is a substantial amount of evidence which points to proper education as one of the most effective ways of delaying the diabetes-related development of complications. Objective. The aim of the study was to investigate the frequency of monitoring blood sugar by diabetic patients and their awareness of nutrition recommendations in diabetes. Materials and methods. The study included 303 patients with type 1 and 2 diabetes. The research tool was a questionnaire based on the KomPAN questionnaire that consisted of a nutrition knowledge test and several questions concerning glycaemic control. The statistical analysis was carried out using the PS IMAGO PRO 5 (IBM SPSS Statistics 25) software. Results. Most of the patients demonstrated a medium level of knowledge – 62% of them provided >50% of the correct answers. Only 8% of the respondents scored >80% of the correct answers. Better test results were achieved by patients with type 1 diabetes. The highest percentage of correct answers was observed in the questions regarding the need to limit sweets or introduce fibre-rich whole-grain products (>90%), the smallest percentage in the questions related to the assessment of carbohydrates and the glycaemic index of selected products (<30%). The majority of the patients checked their blood sugar levels every day, but 6% of them gave up glucose measurements at home. About half of the respondents did not take the HbA1c test – the majority of them were patients with type 2 diabetes. Conclusions. The level of knowledge of the examined patients was unsatisfactory and varied with the type of diabetes. Further education of patients about nutrition and glycaemic control is recommended.
46
Zhang, Yanan, Bin Li, Yating Wang, Shuanghuan Liu, and Haibo Wang. "Paclitaxel Plus Platinum Neoadjuvant Chemotherapy Followed by Surgery Versus Primary Surgery in Locally Advanced Cervical Cancer—A Propensity Score Matching Analysis." Frontiers in Oncology 10 (December 7, 2020). http://dx.doi.org/10.3389/fonc.2020.604308.
Full textAbstract:
ObjectiveTo compare the efficacy and safety of neoadjuvant chemotherapy followed by surgery (NACTS) and primary surgery (PS) in locally advanced cervical cancer (LACC).MethodsLACC (stage IB2/IIA2, FIGO 2009) patients who accepted NACTS or PS in the Cancer Hospital of the Chinese Academy of Medical Sciences from 2007 to 2017 were enrolled, and a database was established. A 1:1 ratio propensity score matching (PSM) was performed for the NACTS group and PS group according to pretreatment characteristics. After PSM, the clinicopathological features and prognosis between the matched groups were compared.ResultsOf 802 cases in the database, 639 met the inclusion criteria, with 428 received paclitaxel plus platinum NACTS, and 211 received PS. After PSM, the two groups had comparable pretreatment characteristics, with 190 cases in each group. In the NACTS group, the operation parameters were similar to the PS group except for the longer operation time (median 255 min vs. 239 min, P = 0.007); pathological intermediate-risk factors including tumor diameter (P < 0.001) and LVSI(+) (P < 0.001) were significantly decreased; fewer patients were with ≥2 intermediate-risk factors (10.5 vs. 53.2%, P < 0.001) so that the rate of adjuvant radiotherapy was reduced (54.2 vs. 70.0%, P = 0.002). DFS and OS were similar between the NACTS group and PS group (P > 0.05). However, for patients with tumor diameter ≥5 cm or SCC ≥5 ng/ml, DFS of the NACTS group was significantly prolonged (P = 0.016, P = 0.007).ConclusionPaclitaxel plus platinum neoadjuvant chemotherapy can reduce adjuvant radiotherapy by decreasing pathological risk factors. Patients with tumor diameter ≥5 cm or SCC ≥5 ng/ml may obtain survival benefits.
47
de Cecco, Bianca S., Fernando F. Argenta, Ronaldo M. Bianchi, Cíntia De Lorenzo, Júlia G. Wronski, Marcele B. Bandinelli, Fernanda VA da Costa, David Driemeier, Saulo P. Pavarini, and Luciana Sonne. "Feline giant-cell pleomorphic sarcoma: cytologic, histologic and immunohistochemical characterization." Journal of Feline Medicine and Surgery, November 18, 2020, 1098612X2097266. http://dx.doi.org/10.1177/1098612x20972667.
Full textAbstract:
Objectives This study aimed to characterize the cytologic, pathologic and immunohistochemical (IHC) aspects of feline giant-cell sarcoma. Methods Biopsy and necropsy reports from the Department of Veterinary Pathology were retrieved, and 13 cases of pleomorphic sarcoma (PS) were selected according to the established epidemiologic, pathologic and IHC criteria. All samples were fixed in 10% formalin, routinely processed for histology, and stained with hematoxylin and eosin. Samples also underwent IHC testing for vimentin, ionized calcium-binding adaptor molecule 1 (Iba-1), desmin, actin and S-100. Results The mean age of the affected cats was 9.5 years, and females were over-represented. Most neoplasms were observed in the flank, lateral thorax, limbs and interscapular region, and were >2 cm in diameter. Cytology analysis revealed highly cellular preparations with three distinct populations (spindle cells, small round cells and multinucleated giant cells) in a dense eosinophilic stroma. Histologically, PS was composed of a combination of these three populations. IHC labeling for vimentin and Iba-1 was strongly positive for spindle cells and multinucleated giant cells, respectively. Desmin/actin showed variable labeling among the samples. S-100 was negative in all samples. Conclusions and relevance PS is a neoplasm of mesenchymal origin, also known as malignant fibrous histiocytoma. The predominant subtype in this study that affected the cats was the giant-cell type, characterized by the presence of multinucleated giant cells among spindle-shaped cells. These findings are similar to those described in human patients; thus, a comparison between the neoplasms seen in these species might be useful, and the knowledge of biologic behavior and overall treatment approach for humans could be extrapolated to cats.
48
"A Computer Dictionary of Literary Arabic: Arabic-English, by Wilson B. Bishai. The Arabic Software Center, 434 William Street, Stoneham, MA 02180. Program includes program disks, Sentinel module. Hardware requirements: IBM PC or AT or XT or PS/2 or equivalent. Minimum requirements: 192K RAM (does not include storage of dictionary); PCDOS or MSDOS or later; parallel port; Color Graphics Adapter or color monitor; 5.25-inch disk drive. Versions I and II allow for use with 2 floppy drives and version III for use with hard disk. Student prices for I and II: $200; III: $300." Middle East Studies Association Bulletin 24, no. 2 (December 1990): 247–48. http://dx.doi.org/10.1017/s0026318400023543.
Full text
49
"Software Reviews : BMDP/PCPublisher: BMDP Statistical Software, Inc. 1440 Sepulveda Blvd., Suite 316, Los Angeles, CA 90025; 310-479-7799 Year of Publication: 1993 Version Reviewed: Release 7.0 Materials: Nine 3.5" or eleven 5.25" floppy disks, 2 statistical software manuals (1500 pp. ), one data manager manual (178 pp.), one BMDP/PC user's guide (204 pp. ), one data entry guide (104 pp.) and one user's digest (251 pp.) Price: $995.00; site licenses available Machine specificity: IBM-PC, Ps/2, and compatibles System Requirements: Pc-DOS or MS-DOS version 3.0 or higher; 11- 27MB hard disk space (includes 5MB needed to run program); 475K free conventional RAM Effectiveness: Very good User Friendliness: Good Documentation: Good." Social Science Computer Review 12, no. 2 (July 1994): 312–14. http://dx.doi.org/10.1177/089443939401200212.
Full text
50
"Software Reviews : NOTA BENE, Version 3.0 Reviewed by Rodney Muth, Fordham University Publisher: Dragonfly Software, 285 West Broadway, Suite 600, New York, NY 10013-2204 (telephone: 212-334-0445) Year of Publication: 1988 Materials: Nine 5.50-inch or five 3.50-inch disks, one manual, one quick reference guide, one tutorial guide, one customization and programming guide, and one installation guide Price: $495 ($275 for students; discounts available from Modem Language Association); $125-195 each for Special Language Supplements Machine Specificity: IBM PC, XT, AT, PS/2, most compatibles System Requirements: Minimum 512K, DOS 2.0 or above, two floppy drives or floppy drive and hard disk Effectiveness: Excellent User-Friendliness: Good to Excellent Documentation: Excellent." Social Science Computer Review 7, no. 3 (October 1989): 395–97. http://dx.doi.org/10.1177/089443938900700323.
Full text